Table 5. Treatment–related treatment-emergent adverse events (TEAE) in the safety population.

System organ class Number (%) of participants	Vacc-4x Safety population (n = 33)
General disorders and administration site conditions     Application site pruritus     Injection site pruritus     Injection site erythema     Influenza-like illness     Asthenia     Application site reaction     Injection site vesicles     Fatigue     Application site erythema     Application site induration     Chest discomfort     Chills     Injection site pain     Injection site reaction	21 (63.6%) 16 (48.5%) 13 (39.4%) 4 (12.1%) 2 (6.1%) 2 (6.1%) 2 (6.1%) 2 (6.1%) 1 (3.0%) 1 (3.0%) 1 (3.0%) 1 (3.0%) 1 (3.0%) 1 (3.0%) 1 (3.0%)
Musculoskeletal and connective tissue disorders     Pain in extremity	1 (3.0%) 1 (3.0%)
Nervous system     Headache     Paraesthesia     Aphasia     Memory impairment	2 (6.1%) 1 (3.0%) 1 (3.0%) 1 (3.0%) 1 (3.0%)
Skin and subcutaneous disorders     Hyperhidrosis     Night sweats     Erythema     Seborrhoeic dermatitis	4 (12.1%) 2 (6.1%) 1 (3.0%) 1 (3.0%) 1 (3.0%)
Gastrointestinal disorders     Nausea     Abdominal pain	1 (3.0%) 1 (3.0%) 1 (3.0%)
Investigations     Aspartate aminotransferase increased	1 (3.0%) 1 (3.0%)

All treatment-related TEAEs are presented. Those listed in bold correspond to >10% of participants.